These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12695433)

  • 1. Diabetes: can we stop the time bomb?
    Fisher M
    Heart; 2003 May; 89 Suppl 2(Suppl 2):ii28-30; discussion ii35-7. PubMed ID: 12695433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trials and clinical practice--bridging the gaps in type 2 diabetes. An evidence-based approach to risk factor modification in type 2 diabetes.
    Greenfield JR; Chisholm DJ
    Aust N Z J Med; 2000 Aug; 30(4):483-91. PubMed ID: 10985515
    [No Abstract]   [Full Text] [Related]  

  • 3. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II.
    Beckman JA; Paneni F; Cosentino F; Creager MA
    Eur Heart J; 2013 Aug; 34(31):2444-52. PubMed ID: 23625211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-prandial hyperglycaemia and prevention of cardiovascular disease.
    Davies MJ
    Diabet Med; 2005 Jan; 22 Suppl 1():6-9. PubMed ID: 15610148
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
    Mazzone T
    Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological treatment of diabetic patients with respect to prevention of macrovascular disease.
    Tkác T
    Acta Diabetol; 2003 Dec; 40 Suppl 2():S338-42. PubMed ID: 14704865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower cholesterol to lower heart risk.
    Clark WL
    Diabetes Self Manag; 2004; 21(3):19, 21-2, 25. PubMed ID: 15206362
    [No Abstract]   [Full Text] [Related]  

  • 8. Getting to the heart of diabetes. Move over, blood sugar. In the fight against diabetes, it's time to focus on managing cholesterol problems and blood pressure, too.
    Harv Heart Lett; 2004 Sep; 15(1):1-2. PubMed ID: 15381493
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular disease.
    Ragucci E; Zonszein J; Frishman WH
    Heart Dis; 2003; 5(1):18-33. PubMed ID: 12549986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The CARDS Study: cardiovascular primary prevention in diabetes patients using Atorvastin].
    Griebenow R
    Internist (Berl); 2005 Mar; 46(3):350-2. PubMed ID: 15696286
    [No Abstract]   [Full Text] [Related]  

  • 11. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
    Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
    JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes and cardiovascular disease.
    Neil A
    Diabetes Obes Metab; 2003 Nov; 5 Suppl 1():S11-8. PubMed ID: 14984017
    [No Abstract]   [Full Text] [Related]  

  • 13. Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system.
    Zimmerman RS; Hobbs TM; Wells BJ; Kong SX; Kattan MW; Bouchard J; Chagin KM; Yu C; Sakurada B; Milinovich A; Weng W; Bauman JM; Pantalone KM
    Diabetes Obes Metab; 2017 Nov; 19(11):1555-1561. PubMed ID: 28407414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Arterial risk in type 2 diabetes: from mega-trials to prescription].
    Bonnet F; Moulin P
    Rev Prat; 2003 May; 53(10):1095-101. PubMed ID: 12846030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials.
    Kunutsor SK; Seidu S; Khunti K
    Diabet Med; 2017 Mar; 34(3):316-327. PubMed ID: 27086572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycaemic control, cardiovascular disease, and mortality in type 2 diabetes.
    Chiasson JL; Le Lorier J
    Lancet; 2014 Nov; 384(9958):1906-7. PubMed ID: 25088436
    [No Abstract]   [Full Text] [Related]  

  • 17. Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance.
    Lebovitz HE
    J Indian Med Assoc; 2008 Nov; 106(11):724-6. PubMed ID: 19368098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing macrovascular disease in patients with type 2 diabetes mellitus.
    Johansen OE; Birkeland KI
    Am J Cardiovasc Drugs; 2003; 3(4):283-97. PubMed ID: 14728081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological strategies to reduce cardiovascular risk in type 2 diabetes mellitus: an update.
    Hovens MM; Tamsma JT; Beishuizen ED; Huisman MV
    Drugs; 2005; 65(4):433-45. PubMed ID: 15733008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular disease in type 2 diabetes mellitus: current management guidelines.
    Mooradian AD
    Arch Intern Med; 2003 Jan; 163(1):33-40. PubMed ID: 12523914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.